Ray D. Page
YOU?
Author Swipe
View article: State of Professional Well-Being, Satisfaction, and Career Plans Among US Oncologists in 2023
State of Professional Well-Being, Satisfaction, and Career Plans Among US Oncologists in 2023 Open
PURPOSE Recent data suggest that the rate of burnout among oncologists has risen over time. In addition to the negative effect of burnout on individuals, widespread burnout may prevent the oncology workforce from meeting patient care needs…
View article: 1237 Deep learning serial CT response score predicts overall survival in advanced NSCLC treated with PD-(L)1 immune checkpoint inhibitors
1237 Deep learning serial CT response score predicts overall survival in advanced NSCLC treated with PD-(L)1 immune checkpoint inhibitors Open
View article: P2.07-06 Real World Efficacy of First-Line Immunotherapy +/- Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics
P2.07-06 Real World Efficacy of First-Line Immunotherapy +/- Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics Open
View article: Achieving White Blood Cell Equity: Are the Safety Profiles of Biosimilar and Reference Pegfilgrastims Comparable?
Achieving White Blood Cell Equity: Are the Safety Profiles of Biosimilar and Reference Pegfilgrastims Comparable? Open
Biosimilars can provide choices for patients and may provide cost savings; however, their uptake has been slow in the USA, in part due to limited knowledge. To provide additional confidence in US pegfilgrastim biosimilars, this narrative r…
View article: Soft Tissue Mass Extramedullary Plasmacytoma Following Radiation Therapy for Solitary Bone Plasmacytoma
Soft Tissue Mass Extramedullary Plasmacytoma Following Radiation Therapy for Solitary Bone Plasmacytoma Open
View article: Exceedingly Rare Bilateral Synchronous Germ Cell Testicular Tumors With Different Histopathological Features
Exceedingly Rare Bilateral Synchronous Germ Cell Testicular Tumors With Different Histopathological Features Open
Bilateral synchronous testicular tumors are a relatively uncommon occurrence, especially when they involve germ cell tumors of different histology. In this context, we present a compelling case report of a male patient who was diagnosed wi…
View article: Supplementary Table Legends from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
Supplementary Table Legends from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer Open
Supplementary Table Legends
View article: Data from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
Data from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer Open
Purpose:Complete and timely tissue genotyping is challenging, leading to significant numbers of patients with newly diagnosed metastatic non–small cell lung cancer (mNSCLC) being undergenotyped for all eight genomic biomarkers recommended …
View article: Supplementary Data from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
Supplementary Data from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer Open
Supplementary Table 1: Detailed assessment of each of the 282 patients. For each of the 282 patients, genomic testing outcome for each modality and each of the eight genomic biomarkers is outlined, as well as KRAS and tissue assessed PD-L1…
View article: Supplementary Table Legends from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
Supplementary Table Legends from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer Open
Supplementary Table Legends
View article: Data from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
Data from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer Open
Purpose:Complete and timely tissue genotyping is challenging, leading to significant numbers of patients with newly diagnosed metastatic non–small cell lung cancer (mNSCLC) being undergenotyped for all eight genomic biomarkers recommended …
View article: Supplementary Data from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
Supplementary Data from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer Open
Supplementary Table 1: Detailed assessment of each of the 282 patients. For each of the 282 patients, genomic testing outcome for each modality and each of the eight genomic biomarkers is outlined, as well as KRAS and tissue assessed PD-L1…
View article: Reducing Avoidable Emergency Visits and Hospitalizations With Patient Risk-Based Prescriptive Analytics: A Quality Improvement Project at an Oncology Care Model Practice
Reducing Avoidable Emergency Visits and Hospitalizations With Patient Risk-Based Prescriptive Analytics: A Quality Improvement Project at an Oncology Care Model Practice Open
PURPOSE: Cancer-related emergency department (ED) visits and hospitalizations that would have been appropriately managed in the outpatient setting are avoidable and detrimental to patients and health systems. This quality improvement (QI) …
View article: 580 Host immune profiling in first-line immunotherapy treated advanced stage non-small cell lung cancer: Results from the INSIGHT registry study
580 Host immune profiling in first-line immunotherapy treated advanced stage non-small cell lung cancer: Results from the INSIGHT registry study Open
Background Immune checkpoint inhibitor therapies (ICI) have revolutionized the treatment of advanced stage non-small cell lung cancer (NSCLC) yielding 5 year-survival in ~30% for ICI treated patients and PD-L1 expression (≥50%) with median…
View article: 1296 Radiomics-based multi-modal prediction of treatment response to PD-1/PD-L1 immune checkpoint inhibitor (ICI) therapy in stage IV non-small cell lung carcinoma (mNSCLC)
1296 Radiomics-based multi-modal prediction of treatment response to PD-1/PD-L1 immune checkpoint inhibitor (ICI) therapy in stage IV non-small cell lung carcinoma (mNSCLC) Open
Background Currently approved biomarkers that predict response to ICIs in mNSCLC are limited to PD-L1 expression levels by immunohistochemistry (IHC) and tumor mutation burden (TMB). However, the predictive performance of PD-L1 IHC and TMB…
View article: Real-World Ibrutinib dose Reductions, Holds and Discontinuations in Chronic Lymphocytic Leukemia
Real-World Ibrutinib dose Reductions, Holds and Discontinuations in Chronic Lymphocytic Leukemia Open
Aim: A retrospective chart review of ibrutinib-treated patients with chronic lymphocytic leukemia (CLL) was conducted. Patients & methods: Adults with CLL who initiated ibrutinib were followed for ≥6 months (n = 180). Resu…
View article: Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer
Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer Open
cfDNA detects guideline-recommended biomarkers at a rate similar to tissue genotyping, and therapeutic outcomes based on plasma-based comprehensive genomic profiling are comparable to published targeted therapy outcomes with tissue profili…
View article: Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer
Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer Open
Purpose Immune checkpoint inhibition (ICI) therapy has improved patient outcomes in advanced non-small cell lung cancer (NSCLC), but better biomarkers are needed. A clinically validated, blood-based proteomic test, or host immune classifie…
View article: MA08.03 Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling.
MA08.03 Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling. Open
View article: Prevalence and predictors of patients reporting adverse drug reactions to health care providers during oral targeted cancer treatment
Prevalence and predictors of patients reporting adverse drug reactions to health care providers during oral targeted cancer treatment Open
Follow-up calls served as an outlet to collect pharmacovigilance data by identifying over 20% of unreported ADRs to HCPs, in which over one-third were moderate to severe. However, future studies are needed to further understand the statist…
View article: Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial Open
View article: Factors associated with adherence to follow-up calls in cancer patients receiving care at a community oncology practice
Factors associated with adherence to follow-up calls in cancer patients receiving care at a community oncology practice Open
Background Follow-up calls in the oncology setting are frequently used to augment care and encourage oral antineoplastic adherence. However, limited data are available on patient populations that would benefit from this intervention versus…
View article: Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study Open
This study validates the safety and efficacy of nivolumab 240 mg Q2W flat-dose monotherapy for previously treated advanced ccRCC and adds to previous safety and efficacy data using the 3 mg/kg Q2W dose.
View article: MA13.05 Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study
MA13.05 Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study Open
View article: A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial Open
Background This randomized, double-blinded, phase II trial evaluated the efficacy of carboplatin and pemetrexed plus either apatorsen, an antisense oligonucleotide targeting heat shock protein (Hsp) 27 mRNA, or placebo in patients with pre…
View article: Opioids and Cancer Pain: Patients’ Needs and Access Challenges
Opioids and Cancer Pain: Patients’ Needs and Access Challenges Open
View article: Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer Open
Purpose: Complete and timely tissue genotyping is challenging, leading to significant numbers of patients with newly diagnosed metastatic non–small cell lung cancer (mNSCLC) being undergenotyped for all eight genomic biomarkers recommended…
View article: Implementing an Electronic End-of-Life Chemotherapy Utilization Measure
Implementing an Electronic End-of-Life Chemotherapy Utilization Measure Open
View article: Reducing Cancer Costs Through Symptom Management and Triage Pathways
Reducing Cancer Costs Through Symptom Management and Triage Pathways Open
Confounding Factor(S), Drawbacks: Certain limitations to the study are acknowledged. We have attempted to identify events that did not actually occur, although we are confident that the methodology used to identify the ER nonevents was rig…
View article: Impact on Oncology Practices of Including Drug Costs in Bundled Payments
Impact on Oncology Practices of Including Drug Costs in Bundled Payments Open
Introduction: This analysis evaluates the impact of bundling drug costs into a hypothetic bundled payment. Methods: An economic model was created for patient vignettes from: advanced-stage III colon cancer and metastatic non–small-cell lun…